{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016659","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.148735+00:00","generated_at":"2026-06-15T02:37:56.712686+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AgeX Q1 2023 net loss widens to $3.3M; cash only $0.3M; going concern flagged","bullets":["Cash, cash equivalents and restricted cash totaled $0.3M as of March 31, 2023.","Owed Juvenescence $33.6M in principal and origination fees; secured note line increased by $4M on May 9.","Q1 revenue $10K (up from $5K YoY); operating expenses $2.2M vs $2.1M.","Net loss attributable to AgeX $3.3M ($0.09 per share) vs $2.7M ($0.07) in prior year.","Company expresses substantial doubt about ability to continue as a going concern."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016659","json":"https://secwatch.observer/filing/0001493152-23-016659.json","markdown":"https://secwatch.observer/filing/0001493152-23-016659.md","text":"https://secwatch.observer/filing/0001493152-23-016659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/0001493152-23-016659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:37:56.712686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b9a6c1f47f8830ed749a1625d088ac2de7de1f2","claim":"Serina Therapeutics, Inc. reported quarter ended March 31, 2023 results: revenue $10,000, net income $3.3 million, EPS ($0.09) per share (basic and diluted).","evidence_excerpt":"and fund each of AgeX’s future draws of that additional amount of credit. First Quarter 2023 Operating Results Revenues: Total Revenues for the first quarter of 2023 were $10,000 as compared with $5,000 in the same period in 2022. Revenues are entirely comprised of sales of research products including stem cell products. Operating expenses: Operating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/0001493152-23-016659-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$10,000"},{"label":"Net income","value":"$3.3 million"},{"label":"EPS","value":"($0.09) per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}